Tag: PRESERVE-003
-
BioNTech’s Gotistobart Posts 18.5-Month Median Survival in Squamous NSCLC
Gotistobart achieved median overall survival of 18.5 months versus 10.0 months with docetaxel in the non-pivotal stage 1 portion of PRESERVE-003.
Gotistobart achieved median overall survival of 18.5 months versus 10.0 months with docetaxel in the non-pivotal stage 1 portion of PRESERVE-003.